University of Sofia KOL Reports Positive Results of Ivermectin Study Targeting Early Onset Mild-to-Moderate COVID-19

University of Sofia KOL Reports Positive Results of Ivermectin Study Targeting Early Onset Mild-to-Moderate COVID-19

Professor Ivo Petrov recently reported the results from his study in Bulgaria are in, and the results are encouraging. The study, conducted on mild-to-moderate early stage cases, led to clear benefits, including expedited reduction of symptoms and reduction of viral activity to accelerated clearance, reported Dr. Petrov. The well-known key opinion leader from the Balkan Peninsula did emphasize Ivermectin is best used early on.

Investigator Point of View

Petrov was quoted in Novinite: “The results are encouraging. It is important to note that the stud was conducted in patients with mild to moderate symptoms in the relatively early stages of the disease. And in such patients Ivermectin has a beneficial effect in terms of faster reduction of symptoms and reduction of activity of the virus, faster clearance of the virus from biological fluids, also much faster, between 4-5 days, in contrast from the penetration of the virus.”

Complementary to Vaccines

Just five days ago, TrialSite reported that the Bulgarian physician and professor of cardiology at the University of Sofia shared with the same Bulgarian agency that vaccines are critical for saving lives. He also noted that drugs such as remdesivir and ivermectin were important as well and in fact were complementary to vaccines. 

In fact, the U.S. government would agree as they just injected $486 million into a global pharmaceutical company to finance large Phase 3 clinical trials for an experimental monoclonal antibody product. The company is on record that in some cases some people won’t be able to take the vaccine (e.g. allergic reactions, etc.), and in other cases, high risk people may need additional protection.

Can the Drug Serve as Pre-Exposure Prophylaxis (PrEP?)

According to Professor Petrov, Ivermectin actually serves to protect the human cell from the viral entry.  He also pointed to mounting evidence that the drug can be preventative—possibly representing an option for PrEP. He pointed to a study of 800 doctors, which revealed that those physicians that actually took the drug had lower incidents of the disease and those that fell ill had less severe symptoms.


TrialSite chronicles different studies and reports around the world. Ivermectin is still not accepted as a potential treatment by most national health authorities, however there is a growing recognition that this could go a long way to help treat large numbers of people, especially in low-to middle-income countries (LMICs)–should there be sufficient evidence for low cost, economical treatments to augment and compliment vaccines. For example, the ANTICOV trial in Sub-Saharan African focuses on potential off-label drugs with the expectation that some poorer nations in Africa may not be able to easily access vaccines.

Moreover, as mentioned earlier, some companies have received large sums of money from the U.S. government to develop monoclonal antibodies, for example, to augment and support a well-balanced, diversified approach to targeting COVID-19.

Lead Research/Investigator

Ivo Petrov, MD, PhD, FESC, FACC, Professor of cardiology at the University of Sofia. One of the pioneers of endovascular therapy in Bulgaria (president of the Bulgarian society of endovascular therapy), he introduced to Bulgaria interventional treatment of carotid stenosis, ischemic stroke, aortic dissension, aortic aneurysm, coronary rotablation, percutaneous recanalization of Leriche syndrome as well as renal denervation. A prominent principal investigator, he has served as a leading investigator in numerous clinical scientific projects.